Netarsudil

Netarsudil
Clinical data
Pronunciationne TAR soo dil
Trade namesRhopressa, Rhokiinsa
Other namesAR-13324
AHFS/Drugs.comMonograph
MedlinePlusa618014
License data
Routes of
administration		Eye drops, topical
ATC code
Legal status
Legal status
Pharmacokinetic data
MetabolismEsterases in the cornea
MetabolitesAR-13503 (active metabolite)
Elimination half-life16–17 hrs
Duration of action≥ 24 hrs
Identifiers
  • [4-[(2S)-3-Amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl]phenyl]methyl 2,4-dimethylbenzoate
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
CompTox Dashboard (EPA)
ECHA InfoCard100.251.524 Edit this at Wikidata
Chemical and physical data
FormulaC28H27N3O3
Molar mass453.542 g·mol−1
3D model (JSmol)
  • Cc1ccc(c(c1)C)C(=O)OCc2ccc(cc2)[C@@H](CN)C(=O)Nc3ccc4cnccc4c3
  • InChI=1S/C28H27N3O3/c1-18-3-10-25(19(2)13-18)28(33)34-17-20-4-6-21(7-5-20)26(15-29)27(32)31-24-9-8-23-16-30-12-11-22(23)14-24/h3-14,16,26H,15,17,29H2,1-2H3,(H,31,32)/t26-/m1/s1
  • Key:OURRXQUGYQRVML-AREMUKBSSA-N

Netarsudil, sold under the brand name Rhopressa among others, is a medication for the treatment of glaucoma.[1][2][3] In the United States, in December 2017, the Food and Drug Administration (FDA) approved a 0.02% ophthalmic solution for the lowering of elevated intraocular pressure in people with open-angle glaucoma or ocular hypertension.[4][5] The European Medicines Agency approved it in 2019 for the same uses under the brand name Rhokiinsa.[2]

The FDA considers it to be a first-in-class medication.[6]

  1. ^ a b "Rhopressa- netarsudil solution/ drops". DailyMed. Retrieved 2 May 2021.
  2. ^ a b c "Rhokiinsa EPAR". European Medicines Agency (EMA). 16 September 2019. Retrieved 27 September 2020.
  3. ^ Dasso L, Al-Khaled T, Sonty S, Aref AA (2018). "Profile of netarsudil ophthalmic solution and its potential in the treatment of open-angle glaucoma: evidence to date". Clinical Ophthalmology. 12. Auckland, N.Z.: 1939–1944. doi:10.2147/OPTH.S154001. PMC 6177382. PMID 30323550.
  4. ^ "Rhopressa (netarsudil) Ophthalmic Solution". U.S. Food and Drug Administration (FDA). 29 January 2018. Retrieved 3 June 2020.
  5. ^ "Aerie (AERI) Gets Early FDA Approval for Lead Drug Rhopressa". 19 December 2017.
  6. ^ New Drug Therapy Approvals 2017 (PDF). U.S. Food and Drug Administration (FDA) (Report). January 2018. Retrieved 16 September 2020.